GCP
ACRV icon

GSA Capital Partners’s Acrivon Therapeutics ACRV Stock Holding History

GSA Capital Partners’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$260K Buy
+186,716
New +$326K 0.02% 1327

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GSA Capital Partners's ACRV Position: Q1 2026 in Review

GSA Capital Partners opened a new position in Acrivon Therapeutics (ACRV) in Q1 2026: 186,716 shares worth $260K. The stake represents 0.02% of the portfolio and ranks #1327 among its holdings.

44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • GSA Capital Partners held 186,716 shares of Acrivon Therapeutics worth $260K as of Q1 2026.
  • Acrivon Therapeutics was a new GSA Capital Partners position in Q1 2026.
  • Acrivon Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1327 holding.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.